Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?-Reference-Cited by-同舟云学术

Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

Published:2022-03 Issue:2 Volume:48 Page:101325
ISSN:1262-3636
Container-title:Diabetes & Metabolism
language:en
Short-container-title:Diabetes & Metabolism

Author:

Scheen Andre J.^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference25 articles.

1. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

2. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus;Scheen;Nat Rev Endocrinol,2020

3. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study;Ueda;BMJ,2018

4. Assessment of the benefit-risk balance of SGLT2 inhibitors: commentary on a new ‘French paradox’;Scheen;Diabetes Metab,2019

5. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials;See;Pharmacology,2021

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs;Journal of Clinical Medicine;2024-08-09

2. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

3. Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies;Diabetes, Obesity and Metabolism;2024-04

4. Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease;JAMA Network Open;2024-03-12

5. A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory;Journal of Clinical Medicine;2024-03-05